Method for treating depression

1. A method for treating a subject, comprising

selecting a subject diagnosed with a psychiatric disorder consisting of major depression, dsythymia or depression with an accompanying anxiety disorder; and

administering 30 to 50 unit equivalents of a Botulinum toxin to a facial muscle in the subject, wherein the facial muscle is a corrugator supercilii muscle, a procerus muscle, or a frontalis muscle;

thereby treating the major depression, the dsythymia or the depression with the accompanying anxiety disorder in the subject.

2. The method of claim 1 , comprising administering to the subject 30 to 50 unit equivalents of a Botulinum toxin to one or both of the corrugator supercilii muscle and the procerus muscle, to cause paralysis of one or both of the corrugator supercilii muscle and the procerus muscle.

3. The method of claim 1 , wherein the Botulinum toxin is Botulinum toxin A.

4. The method of claim 1 , comprising administering about 20-40 Unit equivalents of Botulinum toxin type A to one of more of the corrugator supercilii muscle, the procerus muscle, and the frontalis muscle of the subject.

5. The method of claim 1 , further comprising administering an additional dose of about 30-50 Unit equivalents of Botulinum toxin to the corrugator supercilii muscle, the procerus muscle, or the frontalis muscle of the subject after about two to six months.

6. The method of claim 1 , comprising administering 30 to 50 unit equivalents of a Botulinum toxin to at least two facial muscles in the subject, wherein the facial muscles are the corrugator supercilii muscle, the procerus muscle, and the frontalis muscle.

7. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.

8. The method of claim 7 , wherein the modality of treatment comprises administration of an antidepressant, psychotherapy, or a physical treatment for depression.

9. The method of claim 8 , wherein the antidepressant is a monoamine oxidase inhibitor (MAOI).

10. The method of claim 1 , wherein the subject is diagnosed with a disorder consisting of major depression.

11. The method of claim 1 , wherein the subject is diagnosed with a disorder consisting of dsythymia.

12. The method of claim 1 , wherein the subject is diagnosed with a disorder consisting of depression with an accompanying anxiety disorder.

13. A method for treating a subject, comprising

selecting a subject diagnosed with a disorder consisting of major depression, dsythymia or depression with an accompanying anxiety disorder; and

administering 2 to 5 unit equivalents of a Botulinum toxin to a facial muscle in the subject, wherein the facial muscle is a depressor anguli oris muscle;

thereby treating the major depression, the dsythymia or the depression with the accompanying anxiety disorder in the subject.

14. The method of claim 13 , wherein the Botulinum toxin is Botulinum toxin A.

15. The method of claim 13 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.

16. The method of claim 15 , wherein the modality of treatment comprises administration of an antidepressant, psychotherapy, or a physical treatment for depression.

17. The method of claim 13 , wherein the antidepressant is a selective serotonin reuptake inhibitor (SSRI) or a monoamine oxidase inhibitor (MAOI).

18. The method of claim 13 , wherein the subject is diagnosed with a disorder consisting of major depression.

19. The method of claim 13 , wherein the subject is diagnosed with a disorder consisting of dsythymia.

20. The method of claim 13 , wherein the subject is diagnosed with a disorder consisting of depression with an accompanying anxiety disorder.